By Tyler Durden
Pfizer revealed on Wednesday that it had finally dosed its first patient participating in the Phase 2/3 study examining the efficacy of PF-07321332, an orally administered protease inhibitor antiviral designed to combat COVID-19.
The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF07321332/ritonavir, or a placebo, orally every 12 hours for five days.
Pfizer CEO Albert Bourla weighed in via tweet:
Success against #COVID19 will likely require both vaccines & treatments. Weâre pleased to share weâve started a Phase 2/3 study of our oral antiviral candidateâspecifically designed to combat SARS-CoV-2âin non-hospitalized, low-risk adults: https://t.co/su5VtfbWPX
— Albert Bourla (@AlbertBourla) September 1, 2021
Big Pharma loves to get people mandated on pills for life… like BP meds, and cholesterol meds…etc It’s all a steady returning income for them.. that’s all it is.